NEXT NXT colder weather and a big rise in online sales helped Next to beat expectations for full price sales in the 54 days between 1st November and the 24th December, with a rise of 1.5% as against an expected fall of -0.3%. Within that figure however, retail sales were a disaster with a fall of 6.1% compared to a rise of 13.6% in online sales. Trading for the year as a whole, the 52 weeks to January 2018,was nothing less than disastrous with group profit before tax down by 8.3% slightly better than the expected 9.3%. For 2018 the decline is expected to continue albeit at a reduced rate as subdued consumer demand and a continued decline in real incomes continue to wreak havoc on the high street.
Plus 500 PLUS expects revenue and profits for the year to the 31st December will be ahead of expectations after record revenues were achieved in the fourth quarter, as well as 246,000 new customers.
Oncimmune ONC listed on AIM in May 2016 with its main aim being to enter the Chinese market with its early cancer detection test. The Chinese are heavy smokers and lung cancer deaths alone, now exceed 700,000 each year, due in part to late detection. Oncimmune’s test can detect cancer up to 4 years earlier than conventional methods and the company announced over Christmas that it has reached a distributorship deal with Genostics, a Hong Kong company which has acquired over 6 million shares in Oncimmune at a price of £1.56. Oncimmunes shares jumped to £1.29 yesterday, a rise of 23%
December traffic statistics saw Wizz Air increase capacity by 19.4% and passengers by 19.8%, with load factor up slightly at 87.5%. Ryanair December traffic rose by 3% whilst load factor was up by 1% to 95%